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Long-term adverse outcomes in survivors
of childhood bone sarcoma: the British
Childhood Cancer Survivor Study
M M Fidler1, C Frobisher1, J Guha1, K Wong1, J Kelly1, D L Winter1, E Sugden1, R Duncan2, J Whelan3,
R C Reulen1, M M Hawkins*,1 and on behalf of the British Childhood Cancer Survivor Study (BCCSS) Steering
Group
1Centre for Childhood Cancer Survivor Studies, School of Health and Population Sciences, Public Health Building, University of
Birmingham, Birmingham B15 2TT, UK; 2Orthopaedic Department, Royal Hospital for Sick Children, Yorkhill, Glasgow G3 8SJ, UK
and 3NIHR University College London Hospitals Biomedical Research Centre, London NW1 2PG, UK
Background: With improved survival, more bone sarcoma survivors are approaching middle age making it crucial to investigate
the late effects of their cancer and its treatment. We investigated the long-term risks of adverse outcomes among
5-year bone sarcoma survivors within the British Childhood Cancer Survivor Study.
Methods: Cause-specific mortality and risk of subsequent primary neoplasms (SPNs) were investigated for 664 bone sarcoma
survivors. Use of health services, health and marital status, alcohol and smoking habits, and educational qualifications were
investigated for survivors who completed a questionnaire.
Results: Survivors were seven times more likely to experience all-cause mortality than expected, and there were substantial
differences in risk depending on tumour type. Beyond 25 years follow-up the risk of dying from all-causes was comparable to the
general population. This is in contrast to dying before 25 years where the risk was 12.7-fold that expected. Survivors were also four
times more likely to develop a SPN than expected, where the excess was restricted to 5–24 years post diagnosis. Increased health-
care usage and poor health status were also found. Nonetheless, for some psychosocial outcomes survivors were better off than
expected.
Conclusions: Up to 25 years after 5-year survival, bone sarcoma survivors are at substantial risk of death and SPNs, but this is
greatly reduced thereafter. As 95% of all excess deaths before 25 years follow-up were due to recurrences and SPNs, increased
monitoring of survivors could prevent mortality. Furthermore, bone and breast SPNs should be a particular concern. Since there
are variations in the magnitude of excess risk depending on the specific adverse outcome under investigation and whether the
survivors were initially diagnosed with osteosarcoma or Ewing sarcoma, risks need to be assessed in relation to these factors.
These findings should provide useful evidence for risk stratification and updating clinical follow-up guidelines.
Primary malignant bone sarcomas account for 4.8% of all
childhood cancers in the United Kingdom (Stiller, 2007).
Approximately 65 cases occur each year, of which the principal
tumour types are osteosarcoma (53%) and Ewing sarcoma (39%)
(Stiller, 2007). Although the incidence is low, survival after bone
sarcoma has increased substantially. Since the 1970s 5-year survival
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has risen from 23 to 64% mainly due to the introduction of modern
chemotherapy (Stiller, 2007). Consequently, as the number of
individuals treated for childhood bone sarcomas increases, it
becomes even more important to investigate the risk of the long-
term effects of this childhood cancer and its treatment.
This study assessed adverse outcomes among bone sarcoma
survivors diagnosed between the ages of 0 and 14 years within the
British Childhood Cancer Survivor Study (BCCSS). Key advantages
of the BCCSS compared with other studies are that it is a large,
population-based cohort with 30.4% of individuals diagnosed with
bone sarcoma surviving to age 45 years at least. Therefore, adverse
health and social outcomes beyond 35 years post diagnosis in
these childhood cancer survivors can be examined much more
satisfactorily than has been possible in previous smaller or non-
population-based studies with limited follow-up (Gianinazzi et al,
2013; Jazbec et al, 2004; Cardous-Ubbink et al, 2007; Armstrong
et al, 2009; Casagranda et al, 2013). In this study, we investigated
the long-term risk of premature mortality, developing a subsequent
primary neoplasm, health-care usage, health and marital status,
alcohol and smoking habits, and educational attainment among
5-year childhood bone sarcoma survivors.
MATERIALS AND METHODS
British Childhood Cancer Survivor Study. The BCCSS, which has
been described previously in detail (Hawkins et al, 2008),
is a population-based cohort comprised of 17 980 individuals; it
includes 664 bone sarcoma survivors diagnosed with cancer before the
age of 15, between 1940 and 1991 in Great Britain, and who have
survived at least 5 years. The cohort was ascertained through the
National Registry of Childhood Tumours, which has a high estimated
level of completeness (B99%) (Kroll et al, 2011). Ethical approval for
the study was obtained from a Multi-Centre Research Ethics
Committee and every Local Research Ethics Committee in Britain.
When treatment exposures within this cohort were investigated
across 5-year calendar year bands, we found that before 1976,
where our radiotherapy and chemotherapy treatment completeness
was 98.4% and 88.4%, respectively, the majority of bone sarcoma
survivors received radiotherapy (76.3%), with only a small
proportion receiving chemotherapy. A distinct change in treatment
practice was then observed from 1976 onwards where broadly all
survivors received chemotherapy and Ewing sarcoma survivors
additionally received radiotherapy. Thus, in order to address the
incompleteness of treatment information in more recent diagnosis
years, which was due to decreasing availability of recorded
radiotherapy and chemotherapy details at the National Registry
of Childhood Tumours during this period, our analyses were
undertaken for bone sarcoma survivors overall and separately for
osteosarcoma and Ewing sarcoma, which serve as proxies for
treatment exposures. Therefore, osteosarcoma survivors were likely
to have received radiotherapy if diagnosed before 1976 and only
chemotherapy if diagnosed from 1976 onwards, whereas all Ewing
sarcoma survivors were likely to have received radiotherapy, with
only those diagnosed after 1976 additionally receiving chemother-
apy. Consequently, those surviving beyond 25 years from 5-year
survival were likely to have only received radiotherapy, whilst
those with o25 years follow-up were likely to have received
only chemotherapy or chemotherapy and radiotherapy depending
on tumour type.
Record linkage ascertained outcomes. Deaths and subsequent
primary neoplasms (SPNs) were ascertained for the entire BCCSS
cohort through record linkage with the National Health Service
Information Centre, which includes the population-based national
death and cancer registries. This linkage ensures that the BCCSS is
notified whenever a survivor has died or developed a SPN. To
determine the expected number of deaths or incident cancers,
person-years for each sex-specific, age-specific (5-year bands), and
calendar year-specific (1-year bands) stratum were multiplied by the
corresponding general population rates for specific cause(s) of death
and incident cancers occurring throughout England and Wales.
Cause-specific mortality. For our mortality analysis, the death
certificate and underlying cause of death, as coded by the Office for
National Statistics using the relevant International Classification of
Disease, were obtained. The underlying cause of death was then
confirmed by a clinician using available medical records. Time at risk
started at 5-year survival and continued until individuals exited from
risk at the first occurrence of emigration, death, or 31 December 2010
which was the date of the most recent vital status update on the entire
cohort from the National Health Service Information Centre. The
standardised mortality ratio (SMR) was defined as the ratio of
observed to expected number of deaths. The absolute excess risk
(AER) was defined as the observed minus the expected number of
deaths divided by person-years at risk multiplied by 10 000.
Cumulative mortality for a specific cause of death was calculated by
treating other causes of death as competing risks.
Subsequent primary neoplasms. Confirmation of all SPNs was
undertaken by writing to the relevant clinician(s) to obtain
diagnostic reports to confirm site, type and date of diagnosis.
Time at risk for a SPN began at 5-year survival and individuals
exited from risk at the first occurrence of an SPN, emigration,
death, or 31 December 2006 which was the most recent date up to
which all potential SPNs had been ascertained and validated.
Standardised incidence ratios (SIRs) were calculated as the ratio
of observed to expected number of neoplasms. The AERs
were calculated as described previously for the mortality analyses.
Cumulative incidence for the first occurrence of a SPN was
computed treating death as a competing risk.
Questionnaire ascertained outcomes. Health-care usage, health
and marital status, alcohol and smoking habits, and educational
attainment were obtained via the BCCSS questionnaire. To be
eligible to receive the BCCSS questionnaire survivors in the cohort
had to be alive and aged at least 16 years at questionnaire send-out
(median year 2002). Of the 664 bone sarcoma survivors, 506
survivors met this eligibility criteria and were contacted; amongst
survivors who were ineligible, the majority had died before the
questionnaire send-out (n¼ 106). Ultimately, 411 (81.2%) returned
a completed questionnaire. All comparisons with the general
population were adjusted for age and sex. Some outcomes were
adjusted further—see tables for details.
Health-care usage. Four types of health-care usage were assessed:
talking to a doctor, attending the hospital outpatient department,
being hospitalised as a day patient, and being hospitalised as an
inpatient. In order to compare health-care use with the general
population, the 2002 General Household Survey (GHS) served as
the general population sample (Richards et al, 2004). Multivariable
generalised estimating equation (GEE) logistic regression model-
ling was used to calculate odds ratios (ORs) for health-care usage
among bone sarcoma survivors compared to that expected from
the general population sample (Rebholz et al, 2011).
Psychosocial outcomes. The survivors’ education level, smoking
history, and alcohol consumption were compared with the general
population using the 2002 GHS (Richards et al, 2004) as the
reference sample, whereas marital status was compared with the
National Marriage Registry (Office for National Statistics, 2002).
Multivariable GEE logistic regression was used to compare
educational attainment, smoking status, and alcohol use between
survivors and the general population sample (Frobisher et al, 2007;
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Frobisher et al, 2008; Frobisher et al, 2010; Lancashire et al, 2010).
ORs were calculated using pooled Mantel–Haenszel tests to compare
marital status between survivors and the general population sample.
Health status. Version one of the Short Form 36 (SF-36) Health
Survey was used to measure self-reported health status by the
following eight scales: physical function, role-physical, role-emotional,
social functioning, mental health, vitality, pain, and general health
perception. External comparisons were conducted using the Oxford
Healthy Life Survey (OHLS) as the general population sample.
Multivariable linear regression and direct standardisation were used to
compare bone sarcoma survivors and the OHLS population.
All analyses were undertaken using Stata 12.1 (StataCorp,
College Station, TX, USA). Statistical significance was defined as a
two-sided P-valueo0.05.
RESULTS
Cohort characteristics. Of the 664 bone sarcoma survivors,
309 (46.5%) were diagnosed with osteosarcoma, 260 (39.2%) were
diagnosed with Ewing sarcoma, 26 (3.9%) were diagnosed with
chondrosarcoma, 48 (7.2%) were diagnosed with other specified
bone sarcomas (e.g., fibromatous neoplasms, giant cell tumours,
chordomas, and miscellaneous bone tumours), and 21 (3.2%) were
diagnosed with an unspecified bone sarcoma. The mean age at
diagnosis was 10.8 and the average attained age was 39.4 years
(Table 1). Osteosarcoma survivors were older at diagnosis and had
a higher attained age compared with Ewing sarcoma survivors.
Excluding missing information, 60.2% and 60.0% of survivors
received radiotherapy and chemotherapy, respectively. In general,
characteristics of the 411 survivors who returned a questionnaire
were similar both overall and by tumour type to the entire BCCSS
bone sarcoma cohort, except that only 3.7% had died by 31
December 2010 subsequent to completing a questionnaire.
Record linkage ascertained data
Cause-specific mortality. Overall, bone sarcoma survivors experi-
enced seven times (SMR: 7.0, 95% confidence interval (CI): 5.9–8.3)
the number of deaths expected from the general population with
72 (95% CI: 57.2–85.8) excess deaths per 10 000 person-years
(Table 2). The largest excess was for neoplastic-related causes in
Table 1. Characteristics of bone sarcoma study population overall and by tumour type
Available survivors for data linkage (N¼664) Available questionnaire completed survivors (N¼411)
Characteristic
All
N (%)
Osteosarcoma
n (%)
Ewing sarcoma
n (%)
All
N (%)
Osteosarcoma
n (%)
Ewing sarcoma
n (%)
Sex
Male 345 (52.0) 150 (48.5) 138 (53.1) 200 (48.7) 96 (47.8) 74 (48.1)
Female 319 (48.0) 159 (51.5) 122 (46.9) 211 (51.3) 105 (52.2) 80 (52.0)
Cancer site
Upper limbs 92 (13.9) 34 (11.0) 48 (18.5) 56 (13.7) 21 (10.5) 32 (20.8)
Lower limbs 436 (65.7) 262 (84.8) 132 (50.8) 273 (66.5) 170 (84.6) 75 (48.7)
Bones of skull and face 42 (6.4) 5 (1.6) 10 (3.9) 26 (6.3) 4 (2.0) 6 (3.9)
Vertebral column 24 (3.6) 3 (1.0) 15 (5.8) 13 (3.2) 3 (1.5) 7 (4.6)
Rib, sternum, clavicle 28 (4.2) 1 (0.3) 25 (9.6) 20 (4.9) 1 (0.5) 17 (11.0)
Pelvic, sacrum, coccyx 33 (5.0) 2 (0.7) 27 (10.4) 19 (4.6) 2 (1.0) 15 (9.7)
Other 9 (1.4) 2 (0.7) 3 (1.2) 4 (1.0) 0 (0) 2 (1.3)
Age at diagnosis
Mean (range) 10.8 (0.1–15.0) 11.5 (2.3–15.0) 10.2 (1.5–15.0) 10.8 (1.3–15.0) 11.6 (3.2–15.0) 10.0 (2.0–15.0)
0–4 years 40 (6.0) 8 (2.6) 22 (8.5) 22 (5.4) 4 (2.0) 13 (8.4)
5–9 years 185 (27.9) 74 (24.0) 84 (32.3) 122 (29.7) 46 (22.9) 58 (37.7)
10–14 years 439 (66.1) 227 (73.5) 154 (59.2) 267 (65.0) 151 (75.1) 83 (53.9)
Attained age at exit
Mean (range) 39.4 (7.5–76.8)a 40.9 (10.0–71.9)a 35.7 (7.5–65.2)a 43.3 (22.4–76.8)b 44.6 (22.9–71.9)b 39.4 (22.4–65.2)b
16–24 years 89 (13.4) 31 (10.0) 47 (18.1) 71 (17.3) 23 (11.4) 43 (27.9)
25–34 years 155 (23.3) 62 (20.1) 78 (30.0) 169 (41.1) 83 (41.3) 72 (46.8)
35–44 years 218 (32.8) 108 (35.0) 90 (34.6) 92 (22.4) 53 (26.4) 25 (16.2)
45þ years 202 (30.4) 108 (35.0) 45 (17.3) 79 (19.2) 42 (20.9) 14 (9.1)
Radiotherapyc
No 201 (39.8) 150 (59.3) 17 (9.9) 125 (40.3) 98 (58.3) 10 (10.5)
Yes 304 (60.2) 103 (40.7) 154 (90.1) 185 (59.7) 70 (41.7) 85 (89.5)
Chemotherapyc
No 195 (40.0) 93 (37.5) 40 (23.8) 109 (36.7) 58 (35.6) 16 (17.2)
Yes 292 (60.0) 155 (62.5) 128 (76.2) 188 (63.3) 105 (64.4) 77 (82.8)
Surgeryc
No 160 (31.3) 34 (13.2) 109 (63.4) 93 (29.4) 19 (11.1) 62 (64.6)
Yes 352 (68.8) 223 (86.8) 63 (36.6) 223 (70.6) 152 (88.9) 34 (35.4)
Vital statusa
Alive 533 (80.3) 256 (82.9) 203 (78.1) 396 (96.4) 193 (96.0) 150 (97.4)
Dead 131 (19.7) 53 (17.2) 57 (21.9) 15 (3.7) 8 (4.0) 4 (2.6)
aAge at 31 December 2010 or death/embarkation (if before 31 December 2010)—relevant to the mortality analyses.
bAge at questionnaire completion—relevant to outcomes measured by the questionnaire.
cMissing data: radiotherapy (all data linkage)¼ 139, radiotherapy (all questionnaire)¼ 101; chemotherapy (all data linkage)¼ 157, chemotherapy (all questionnaire)¼ 114; surgery (all data
linkage)¼ 152, Surgery (all questionnaire)¼ 95.
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both relative and absolute terms; recurrences and SPNs accounted
for 71.2% and 22.6% of all excess deaths, respectively. When the
SMR was assessed by follow-up, a striking difference was observed;
the overall SMR was 12.7-times (95% CI: 10.5–15.2) that expected
during 0–24 years follow-up and only 1.7-times (95% CI:1.0–2.7)
that expected beyond 25 years. Notably, there was an 8-fold
decrease in SMRs from 0–24 years to beyond 25 years follow-up
for SPN-related deaths. Compared with the general population, the
SMR for all-causes was significantly higher (Po0.001) for Ewing
sarcoma survivors, who had approximately double the SMR
and AER of osteosarcoma survivors. Although recurrence and
SPN-related deaths accounted for B93% of all excess deaths in
both tumour types, there was heterogeneity in the proportion of
recurrence and SPN excess deaths; recurrences accounted for
59.0% and 80.2% of excess deaths in osteosarcoma and Ewing
sarcoma survivors, respectively, whilst the corresponding excess
SPN deaths were 34.7% and 13.1%.
There was a steep increase in mortality during the initial 5 years
following 5-year survival where the cumulative mortality reached
10.4% (95% CI: 8.3–13.0) (Supplementary Figure 1). Subsequently,
there was a more gradual incline to 20.6% (95% CI: 17.3–24.3) at
35 years post diagnosis. When stratified by tumour type (Figure 1)
a significant difference (P¼ 0.004) in cumulative mortality was
observed for recurrences, where Ewing sarcoma survivors had
nearly double the cumulative mortality at 35 years post diagnosis
(osteosarcoma: 8.5% vs Ewing sarcoma: 16.7%). Conversely,
the cumulative mortality due to SPNs was twice as high for
osteosarcoma compared with Ewing sarcoma survivors at the same
point (osteosarcoma: 6.7% vs Ewing sarcoma: 3.2%).
Subsequent primary neoplasms. Bone sarcoma survivors were
4.4-times (95% CI: 3.3–5.8) more likely to experience a SPN than
expected and had 29.3 (95% CI: 18.7–39.9) excess SPNs per 10 000
person-years (Table 3). By SPN cancer type, survivors overall and
by tumour type were at a considerably higher risk of developing a
subsequent bone neoplasm and to a lesser extent a breast
neoplasm. Specifically overall, survivors were 136.3- (95% CI:
79.2–234.8) and 4.5-times (95% CI: 2.6–8.0) more at risk than the
general population for bone and breast cancers, respectively. When
the SIRs were assessed by follow-up, a 8.4-fold (95% CI: 6.1–11.2)
increased risk was observed during 0–24 years, where the SIR for
subsequent breast and bone cancer were 10.8 (95% CI: 5.2–19.9)
and 154.3 (95% CI: 82.2–263.8), respectively. Beyond 25 years of
Cumulative mortality by tumour type
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Figure 1. Cumulative mortality of recurrence and second primary
neoplasms among childhood bone sarcoma survivors within the British
Childhood Cancer Survivor Study (BCCSS) by tumour type.
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follow-up, the SIR for any SPN was not significantly higher in
survivors than expected from the general population.
There was a continuous and steady increase in cumulative
incidence for SPNs over follow-up, ultimately reaching 8.3% (95%
CI: 5.9–11.2) at 30 years post diagnosis (Supplementary Figure 2).
When stratified by tumour type, the cumulative incidence curves
were nearly identical to each other and to bone sarcoma survivors
overall (P40.05).
Questionnaire ascertained data
Health-care usage. Compared with the general population sample,
bone sarcoma survivors were almost three times (OR: 2.9, 95% CI:
2.3–3.7) more likely to have visited an outpatient hospital
department in the previous three months (Table 4). Survivors
were also over twice (OR: 2.4, 95% CI: 1.7–3.4) more likely to be
hospitalised as an inpatient during the previous year than the
general population sample. When analysed by tumour type, both
osteosarcoma and Ewing sarcoma survivors had significantly
higher odds of attending the hospital as an outpatient or inpatient
than expected.
Psychosocial outcomes. Bone sarcoma survivors overall were
comparable to the general population sample for being ever-
married, a current drinker, or consuming harmful amounts of
alcohol (Table 4). Survivors were, however, significantly less likely
to be a current smoker (OR: 0.6, 95% CI: 0.5–0.8) and consume
alcohol over recommendations (OR: 0.7, 95% CI: 0.5–0.9) than the
general population sample. Compared to that expected, survivors
performed well in obtaining educational qualifications and were
70% more likely to have obtained at least O-levels (OR: 1.7, 95%
CI: 1.3–2.1). When analysed by tumour type, the odds for each
psychosocial outcome were comparable to the overall finding.
Health status. Compared with the general population sample,
bone sarcoma survivors overall were significantly more limited in
all SF-36 scales with the exception of role-emotional (Figure 2).
The most notable differences occurred in physical function, role-
physical, and pain. For the individual components of the physical
function scale (Supplementary Figure 3), 54% and 61% of survivors
were limited in ‘moderate activities’ and ‘walking more than one
mile’ compared with the 8% and 11% expected from the general
population sample, respectively. In the role-physical scale
(Supplementary Figure 4), the largest difference between the
survivors and general population sample was in ‘being limited in
the kind of work and activities’, although all component questions
reported at least a 10% deficit. Finally, for the pain scale
(Supplementary Figure 5), survivors reported more bodily pain
(12% vs 5%) and more pain interference (16% vs 5%) during the
past 4 weeks compared with the general population sample.
When stratified by tumour type, osteosarcoma survivors were
assessed additionally by amputation status, where only arm or leg
amputations as a form of initial treatment for the first primary
tumour were included. Compared with the general population
sample, osteosarcoma amputee survivors reported being the most
limited in all scales relative to osteosarcoma non-amputees and
Ewing sarcoma survivors, with a significantly (Po0.001) higher
disadvantage in physical function (Figure 2).
DISCUSSION
This is the first large-scale population-based study to provide a
comprehensive description of long-term health and social outcomes
among a large cohort of 5-year bone sarcoma survivors, both overall
and by tumour type, beyond 35 years post diagnosis. Mortality
estimates in this cohort were elevated seven times that expected andT
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varied significantly between tumour types, which were consistent
with previous findings of a large-scale US study (Armstrong et al,
2009). Past studies have also shown the principal cause of death was
neoplastic-related (MacArthur et al, 2007; Ginsberg et al, 2010;
Nagarajan et al, 2011). However, to our knowledge, this is the first
study that has shown substantial differences when comparing excess
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Figure 2. Sex and age adjusted regression coefficients and corresponding 95% confidence intervals for differences in SF-36 health status scales
between bone sarcoma, osteosarcoma amputees, osteosarcoma non-amputees, and Ewing sarcoma survivors vs UK norms.
Table 4. Percentages and odds ratios (with corresponding 95% CIs) for the likelihood of use of health services and psychosocial
outcomes in bone sarcoma survivors within the British Childhood Cancer Survivor Study (BCCSS) compared with the general
population of Britain
UK norms (ref)
Bone sarcoma overall
OR (95% CI)
Osteosarcoma
OR (95% CI)
Ewing sarcoma
OR (95% CI)
Marital Statusa
Males ever-married 1.0 0.7 (0.5, 1.0) 1.0 (0.6, 1.6) 0.7 (0.4, 1.3)
Females ever-married 1.0 0.8 (0.6, 1.1) 0.8 (0.5, 1.2) 0.9 (0.6, 1.4)
Educationb
University degree or higher 1.0 1.2 (1.0, 1.6) 1.5 (1.1, 2.1) 1.0 (0.8, 1.5)
Teaching qualification or higher 1.0 1.1 (0.9, 1.4) 1.3 (1.0, 1.7) 1.0 (0.7, 1.4)
A-levels or higherc 1.0 1.2 (1.0, 1.5) 1.2 (0.9, 1.6) 1.1 (0.8, 1.5)
O-levels or higherd 1.0 1.7 (1.3, 2.1) 1.8 (1.2, 2.6) 2.0 (1.2, 3.1)
Alcohole
Current drinker 1.0 0.8 (0.6, 1.1) 1.0 (0.6, 1.6) 0.8 (0.5, 1.3)
Consuming over recommendations 1.0 0.7 (0.5, 0.9) 0.7 (0.5, 1.1) 0.5 (0.3, 0.9)
Consuming harmful amounts 1.0 0.7 (0.4, 1.1) 0.6 (0.3, 1.4) 0.7 (0.3, 1.5)
Smokinge
Current smoker 1.0 0.6 (0.5, 0.8) 0.7 (0.5, 1.0) 0.6 (0.4, 0.9)
Use of health servicesf
Talked to a doctorg 1.0 1.2 (0.9, 1.6) 1.3 (0.9, 1.8) 1.2 (0.8, 1.8)
Attended as outpatientg 1.0 2.9 (2.3, 3.7) 2.9 (2.1, 4.0) 3.2 (2.2, 4.7)
Attended as day patienth 1.0 1.1 (0.7, 1.5) 1.2 (0.7, 1.9) 1.0 (0.6, 1.8)
Attended as inpatienth 1.0 2.4 (1.7, 3.4) 2.5 (1.6, 3.9) 2.8 (1.7, 4.7)
Abbreviations: OR¼odds ratio; CI¼ confidence interval.
aFrom a pooled Mantel–Haenszel model controlling for attained age.
bFrom a GEE multivariable logistic regression controlling for age at questionnaire completion and sex (taking into account the GHS weighting factor).
cDegree received at age 16.
dDegree received at age 18.
eFrom a GEE multivariable logistic model adjusting for attained age (p69 years), sex, marital status, socioeconomic classification, educational attainment, and region (taking into account the
GHS weighting factor).
fFrom a GEE multivariable logistic model adjusting for age at questionnaire completion, sex, and educational attainment.
gExcluding women who were pregnant at time of survey.
hExcluding visits for having a baby.
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and cumulative mortality between tumour types; osteosarcoma
survivors had double the cumulative mortality for SPNs compared
with Ewing sarcoma and Ewing sarcoma survivors had double the
cumulative mortality for recurrences compared with osteosarcoma at
35 years post diagnosis. The osteosarcoma survivors in this study
were much more likely to have an amputation than Ewing sarcoma,
which may partially explain why osteosarcoma survivors were less
likely to have recurred (Grimer et al, 2002). Additionally, due to the
extended follow-up available, this is the first study to show that
beyond 25 years follow-up the risk of dying from all-causes is
comparable to the general population and unlikely to exceed
2.7-fold that expected. This is in contrast to dying before 25 years
of follow-up, where the risk is 12.7-fold that expected. This provides
important evidence for clinicians who monitor survivors treated in
similar decades to those included in the BCCSS. A possible
explanation for this striking absence or low risk of excess mortality
with extended follow-up may relate to our previous observation that,
as the overall cohort of childhood cancer survivors ages, a large
proportion of excess deaths are attributed to SPNs (Reulen et al,
2010), particularly breast, digestive, genitourinary, and lung carcino-
mas. Although carcinomas of these sites are common cancers of
adulthood in the general population, in childhood cancer survivors
they are principally caused by direct radiotherapy exposure (Reulen
et al, 2011). As 80% of the bone sarcomas included here were
diagnosed in the limb, there is unlikely to have been much direct
exposure from radiotherapy to tissues of these sites due to the lack of
proximity of the radiotherapy fields.
The overall and tumour type-specific SIRs for SPNs were
consistent with previous studies (Magnani et al, 1996; Cardous-
Ubbink et al, 2007; Inskip and Curtis, 2007; Friedman et al, 2010).
Additionally, our findings are consistent with previous literature in
that the most common SPN was breast cancer for osteosarcoma
survivors and bone cancer for Ewing sarcoma survivors
(Inskip and Curtis, 2007). Due to the extended follow-up available,
this is the first study to show that the risk of developing SPNs was
9.9-fold the expected during 0–24 years follow-up and comparable
to the general population beyond 25 years follow-up, where it was
unlikely to exceed 2.0-fold that expected. Notably, all thirteen bone
cancers occurred before 25 years follow-up, nine of which
developed inside or on the edge of tissue directly irradiated to
treat the original bone sarcoma and one in a survivor diagnosed
with a p53 mutation. This corresponds with our previous work that
found that bone cancer is the most common SPN after a first
primary bone sarcoma (Reulen et al, 2011), which is principally
attributable to exposure of the SPN site to radiation during
treatment for the first cancer (Tucker et al, 1987; Hawkins et al,
1996; Schwartz et al, 2014). Of the two breast cancers observed
subsequent to 25 years follow-up, both developed in survivors
previously treated for a bone sarcoma of a lower limb with
unknown p53 status.
Consistent with other studies (Eiser et al, 2001; Hudson et al,
2003; Zeltzer et al, 2008), we reported that survivors were severely
limited in health status, in particular physical function and pain.
Although previous studies have suggested that health status among
amputees is generally similar to non-amputees (Eiser and Grimer,
1999; Nagarajan et al, 2004; Paul, 2008; Eiser, 2009; Nagarajan
et al, 2009; Barrera et al, 2012), we found that osteosarcoma
amputees reported the worst health status for all scales, with
significantly higher limitations in physical function relative to
osteosarcoma non-amputees and Ewing sarcoma (95% of which
were non-amputees) survivors.
Although we report here on appreciable proportions of the bone
sarcoma survivors experiencing detrimental effects to their health,
many of their social outcomes were favourable. In fact, our findings
suggest that survivors were more likely than expected to obtain
some types of educational qualification and less likely to be a
current smoker than expected from the general population.
Current guidelines and recommendations. The Bone Cancer
Research Trust currently recommends yearly follow-up after 5-year
survival (Newby and Unsworth, 2013a, 2013b). From the evidence
presented here, 74% and 21% of all excess deaths before 25 years of
follow-up were due to recurrence and SPN, respectively, and
therefore monitoring of survivors for recurrences and SPNs,
particularly during the period 5–10 years post diagnosis where risk
of recurrence is highest, could help prevent premature mortality.
Bone and breast SPNs should also be a particular concern
and regular follow-up should be provided, particularly in the
period 0–24 years following 5-year survival for bone SPNs.
Factsheets given to childhood cancer survivors could further
expand upon the risk of recurrence and SPNs and the potential for
early diagnosis by detailing more precisely signs and symptoms
relating to bone and breast neoplasms. Furthermore, the
substantial excess risks of specific physical limitations and pain
are likely to be useful for risk stratification and possible
interventions that seek to reduce morbidity and the practical
difficulties that survivors may face.
Limitations. Although the findings in this paper may not be
generalisable for children diagnosed after 1991, the purpose of this
study was to address the long-term, beyond 35 years post
diagnosis, outcomes that childhood bone sarcoma survivors are
currently facing. We acknowledge reassessment is necessary and
recommend further analyses to be conducted on the recently
extended BCCSS cohort, which includes 5-year survivors diag-
nosed from 1992 to 2006. Furthermore, as a large proportion of
bone sarcoma diagnoses occur in individuals aged over 14 years,
we recommend further analyses on adverse outcomes to be
assessed using the Teenage and Young Adult Cancer Survivor
Study (TYACSS), which we have established recently and includes
all 5-year survivors diagnosed from age 15–39 in England and
Wales between 1970 and 2006. Finally, a potential limitation of our
study is the lack of detailed treatment information. Although we
report a large reduction in excess mortality and SPNs beyond 25
years follow-up, those followed-up foro25 years are more likely to
be treated differently due to the introduction of chemotherapy.
Thus, reassessment of these more recently diagnosed individuals is
essential in order to determine whether the decreases in risk
reported in this study remain with newer treatment practices.
Nevertheless, due to our population-based design, the evidence
presented here provides a reliable and unbiased basis to update
clinical follow-up guidelines in relation to bone sarcoma survivors
diagnosed before age 15 and treated before 1992 in Great Britain by
using cancer diagnosis as a proxy.
CONCLUSIONS
In conclusion, childhood bone sarcoma survivors diagnosed
between 1940 and 1991 in this cohort are at substantial risk of
death and SPNs up to 25 years after 5-year survival, but the risk is
greatly reduced thereafter. Survivors additionally face difficulties in
daily life due to their excess prevalence of poor physical health
status. As there are variations in the degree of excess depending on
the specific outcome and whether they survived osteosarcoma or
Ewing sarcoma, risk needs to be assessed in a stratified way. These
findings should provide useful evidence for risk stratification,
updating clinical follow-up guidelines, and possible intervention
studies.
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